{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,31]],"date-time":"2026-10-31T02:32:58Z","timestamp":1793413978156,"version":"4.5.0"},"reference-count":77,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2024,6,1]],"date-time":"2024-06-01T00:00:00Z","timestamp":1717200000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2024,6,1]],"date-time":"2024-06-01T00:00:00Z","timestamp":1717200000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2025,6,11]],"date-time":"2025-06-11T00:00:00Z","timestamp":1749600000000},"content-version":"am","delay-in-days":375,"URL":"http:\/\/www.elsevier.com\/open-access\/userlicense\/1.0\/"},{"start":{"date-parts":[[2024,6,1]],"date-time":"2024-06-01T00:00:00Z","timestamp":1717200000000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2024,6,1]],"date-time":"2024-06-01T00:00:00Z","timestamp":1717200000000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2024,6,1]],"date-time":"2024-06-01T00:00:00Z","timestamp":1717200000000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2024,6,1]],"date-time":"2024-06-01T00:00:00Z","timestamp":1717200000000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2024,6,1]],"date-time":"2024-06-01T00:00:00Z","timestamp":1717200000000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"content-domain":{"domain":["clinicalkey.fr","clinicalkey.jp","clinicalkey.es","clinicalkey.com.au","clinicalkey.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Schizophrenia Research"],"published-print":{"date-parts":[[2024,6]]},"DOI":"10.1016\/j.schres.2023.08.002","type":"journal-article","created":{"date-parts":[[2023,8,24]],"date-time":"2023-08-24T17:30:27Z","timestamp":1692898227000},"page":"312-322","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":25,"special_numbering":"C","title":["Clozapine and neutrophil response in patients of African descent: A six-month, multinational, prospective, open-label clinical trial"],"prefix":"10.1016","volume":"268","author":[{"given":"Deanna L.","family":"Kelly","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Matthew","family":"Glassman","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ikwunga","family":"Wonodi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gopal","family":"Vyas","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Charles M.","family":"Richardson","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Evaristus","family":"Nwulia","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Heidi J.","family":"Wehring","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Taiwo","family":"Oduguwa","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marie","family":"Mackowick","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Maria Mananita S.","family":"Hipolito","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Olawunmi","family":"Peters","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Narayan","family":"Rai","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jaeboon","family":"Park","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Adeola O.","family":"Adebayo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"David A.","family":"Gorelick","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Elaine","family":"Weiner","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Fang","family":"Liu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ann Marie","family":"Kearns","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Heather A.","family":"Adams","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Raymond C.","family":"Love","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shuo","family":"Chen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ayodeji","family":"Olaniyan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nicholas","family":"Ambulos","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Darius","family":"McKoy","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Madhulika C.","family":"Nallani","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sophie","family":"Lanzkron","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mulu","family":"Mengistab","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Brian","family":"Barr","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Erica","family":"Davis","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rahman","family":"Lawal","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Robert W.","family":"Buchanan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Richard","family":"Adebayo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"3","key":"10.1016\/j.schres.2023.08.002_bb0005","doi-asserted-by":"crossref","first-page":"301","DOI":"10.1007\/s002130051008","article-title":"Circadian rhythm of white blood cells during clozapine treatment","volume":"144","author":"Ahokas","year":"1999","journal-title":"Psychopharmacology"},{"key":"10.1016\/j.schres.2023.08.002_bb0010","unstructured":"American Psychiatric Association, (2000). Diagnostic and Statistical Manual of Mental Disorders 4th Edition TR (DSM-IV). Washington, DC."},{"key":"10.1016\/j.schres.2023.08.002_bb0015","doi-asserted-by":"crossref","first-page":"48","DOI":"10.1016\/j.schres.2022.02.009","article-title":"Re-examining the utility and validity of benign ethnic neutropenia: A narrative literature review","volume":"253","author":"Andreou","year":"2023","journal-title":"Schizophr. Res."},{"issue":"1","key":"10.1016\/j.schres.2023.08.002_bb0020","doi-asserted-by":"crossref","first-page":"37","DOI":"10.1111\/acps.12742","article-title":"International trends in clozapine use: a study in 17 countries","volume":"136","author":"Bachmann","year":"2017","journal-title":"Acta Psychiatr. Scand."},{"key":"10.1016\/j.schres.2023.08.002_bb0025","doi-asserted-by":"crossref","first-page":"672","DOI":"10.1192\/bjp.154.5.672","article-title":"A rating scale for drug-induced akathisia","volume":"154","author":"Barnes","year":"1989","journal-title":"Br. J. Psychiatry"},{"key":"10.1016\/j.schres.2023.08.002_bb0030","article-title":"Clozapine, neutropenia and Covid-19: should clinicians be concerned? 3 months report","volume":"13","author":"Bonaccorso","year":"2021","journal-title":"Brain Behav Immun Health"},{"key":"10.1016\/j.schres.2023.08.002_bb0035","doi-asserted-by":"crossref","first-page":"50","DOI":"10.1016\/j.schres.2017.03.045","article-title":"Elevated clozapine levels associated with infection: A systematic review","volume":"192","author":"Clark","year":"2018","journal-title":"Schizophr. Res."},{"issue":"1","key":"10.1016\/j.schres.2023.08.002_bb0040","doi-asserted-by":"crossref","first-page":"73","DOI":"10.1016\/S0006-3223(99)00029-3","article-title":"Treatment-resistant schizophrenic patients respond to clozapine after olanzapine non-response","volume":"46","author":"Conley","year":"1999","journal-title":"Biol. Psychiatry"},{"issue":"3","key":"10.1016\/j.schres.2023.08.002_bb0045","doi-asserted-by":"crossref","first-page":"320","DOI":"10.1176\/appi.ps.56.3.320","article-title":"Comparison of clozapine use in Maryland and in Victoria, Australia","volume":"56","author":"Conley","year":"2005","journal-title":"Psychiatr. Serv."},{"key":"10.1016\/j.schres.2023.08.002_bb0050","doi-asserted-by":"crossref","first-page":"519","DOI":"10.2147\/NDT.S225643","article-title":"Negative symptoms in schizophrenia: A review and clinical guide for recognition, assessment, and treatment","volume":"16","author":"Correll","year":"2020","journal-title":"Neuropsychiatr. Dis. Treat."},{"issue":"1","key":"10.1016\/j.schres.2023.08.002_bb0055","doi-asserted-by":"crossref","first-page":"39","DOI":"10.1177\/0957154X07070335","article-title":"The history of clozapine and its emergence in the US market: a review and analysis","volume":"18","author":"Crilly","year":"2007","journal-title":"Hist Psychiatry"},{"key":"10.1016\/j.schres.2023.08.002_bb0060","unstructured":"DeFaria C and da Costa Dourado C. (2022). \" Neutropenia.\" Medscape Drugs and Diseases, from ttps:\/\/emedicine.medscape.com\/article\/204821-overview."},{"key":"10.1016\/j.schres.2023.08.002_bb0065","first-page":"3","article-title":"Prevalence, phenotype and inheritance of benign neutropenia in Arabs","volume":"9","author":"Denic","year":"2009","journal-title":"BMC Blood Disord"},{"issue":"1","key":"10.1016\/j.schres.2023.08.002_bb0070","first-page":"66","article-title":"Assessment of capacity to give consent to research participation: state-of-the-art and beyond","volume":"1","author":"DeRenzo","year":"1998","journal-title":"J Health Care Law Policy"},{"issue":"4","key":"10.1016\/j.schres.2023.08.002_bb0075","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0036308","article-title":"Haematological and biochemical reference values for healthy adults in the middle belt of Ghana","volume":"7","author":"Dosoo","year":"2012","journal-title":"PLoS One"},{"issue":"11","key":"10.1016\/j.schres.2023.08.002_bb0080","doi-asserted-by":"crossref","first-page":"1453","DOI":"10.1176\/appi.ps.54.11.1453","article-title":"Psychopharmacology: underuse of evidence-based treatments in psychiatry","volume":"54","author":"Fayek","year":"2003","journal-title":"Psychiatr Serv"},{"key":"10.1016\/j.schres.2023.08.002_bb0085","unstructured":"First, M. B. and M. Gibbon (2004). \"The structured clinical interview for DSM-IV axis I disorders (SCID-I) and the structured clinical interview for DSM-IV axis II disorders (SCID-II).\" 2: 134\u2013143."},{"issue":"2","key":"10.1016\/j.schres.2023.08.002_bb0090","doi-asserted-by":"crossref","first-page":"115","DOI":"10.2174\/157488608784529251","article-title":"Side effects of clozapine and some other psychoactive drugs","volume":"3","author":"Flanagan","year":"2008","journal-title":"Curr. Drug Saf."},{"issue":"3","key":"10.1016\/j.schres.2023.08.002_bb0095","doi-asserted-by":"crossref","first-page":"368","DOI":"10.1377\/hlthaff.2021.01432","article-title":"Despite the FDA\u2019s five-year plan, black patients remain inadequately represented in clinical trials for drugs: study examines FDA\u2019s five-year action plan aimed at improving diversity in and transparency of pivotal clinical trials for newly-approved drugs","volume":"41","author":"Green","year":"2022","journal-title":"Health Aff."},{"key":"10.1016\/j.schres.2023.08.002_bb0100","series-title":"ECDEU Assessment Manual for Psychopharmacology","first-page":"534","author":"Guy","year":"1976"},{"issue":"1","key":"10.1016\/j.schres.2023.08.002_bb0105","doi-asserted-by":"crossref","first-page":"15","DOI":"10.1053\/lc.1999.v133.a94931","article-title":"Benign ethnic neutropenia: what is a normal absolute neutrophil count?","volume":"133","author":"Haddy","year":"1999","journal-title":"J. Lab. Clin. Med."},{"issue":"7","key":"10.1016\/j.schres.2023.08.002_bb0110","doi-asserted-by":"crossref","first-page":"486","DOI":"10.7326\/0003-4819-146-7-200704030-00004","article-title":"Prevalence of neutropenia in the U.S. population: age, sex, smoking status, and ethnic differences","volume":"146","author":"Hsieh","year":"2007","journal-title":"Ann. Intern. Med."},{"issue":"8","key":"10.1016\/j.schres.2023.08.002_bb0115","doi-asserted-by":"crossref","first-page":"869","DOI":"10.1001\/archinte.165.8.869","article-title":"Population-based drug-induced agranulocytosis","volume":"165","author":"Ib\u00e1\u00f1ez","year":"2005","journal-title":"Arch. Intern. Med."},{"issue":"1","key":"10.1016\/j.schres.2023.08.002_bb0120","doi-asserted-by":"crossref","first-page":"441","DOI":"10.1186\/s12888-016-1167-0","article-title":"Neutropenia and agranulocytosis during treatment of schizophrenia with clozapine versus other antipsychotics: an observational study in Iceland","volume":"16","author":"Ingimarsson","year":"2016","journal-title":"BMC Psychiatry"},{"key":"10.1016\/j.schres.2023.08.002_bb0125","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1186\/s12888-016-1167-0","article-title":"Neutropenia and agranulocytosis during treatment of schizophrenia with clozapine versus other antipsychotics: an observational study in Iceland","volume":"16","author":"Ingimarsson","year":"2016","journal-title":"BMC psychiatry"},{"key":"10.1016\/j.schres.2023.08.002_bb0130","doi-asserted-by":"crossref","first-page":"79","DOI":"10.2147\/JBM.S16214","article-title":"Subclinical leukopenia in a cross section of Nigerian blood donors","volume":"2","author":"Jeremiah","year":"2011","journal-title":"J Blood Med"},{"issue":"9","key":"10.1016\/j.schres.2023.08.002_bb0135","doi-asserted-by":"crossref","first-page":"789","DOI":"10.1001\/archpsyc.1988.01800330013001","article-title":"Clozapine for the treatment-resistant schizophrenic. A double-blind comparison with chlorpromazine","volume":"45","author":"Kane","year":"1988","journal-title":"Arch. Gen. Psychiatry"},{"key":"10.1016\/j.schres.2023.08.002_bb0140","unstructured":"Kearns A.G.M., Vyas G, Hunt J, Dadkhoo D, Ezana D, Adams HA, Trikeriotis S, Palachuvattil J, Richardson CM, Kelly DL. (2023). Inclusion of Court Ordered Patients\/Prisoners in Psychiatric Research. Presented at the Congress of the Schizophrenia International Research Society May 11\u201316, 2023 Toronto, Canada."},{"issue":"9","key":"10.1016\/j.schres.2023.08.002_bb0145","doi-asserted-by":"crossref","first-page":"1404","DOI":"10.4088\/JCP.v67n0911","article-title":"Clozapine utilization and outcomes by race in a public mental health system: 1994-2000","volume":"67","author":"Kelly","year":"2006","journal-title":"J Clin Psychiatry"},{"issue":"1","key":"10.1016\/j.schres.2023.08.002_bb0150","doi-asserted-by":"crossref","first-page":"92","DOI":"10.3371\/CSRP.1.1.8","article-title":"Why not clozapine?","volume":"1","author":"Kelly","year":"2007","journal-title":"Cliinical Schizophrenia & Related Psychoses"},{"issue":"5","key":"10.1016\/j.schres.2023.08.002_bb0155","doi-asserted-by":"crossref","first-page":"1221","DOI":"10.1093\/schbul\/sbl068","article-title":"Clozapine underutilization and discontinuation in African Americans due to leucopenia","volume":"33","author":"Kelly","year":"2007","journal-title":"Schizophr. Bull."},{"issue":"4","key":"10.1016\/j.schres.2023.08.002_bb0160","doi-asserted-by":"crossref","first-page":"374","DOI":"10.1097\/JCP.0000000000000345","article-title":"Adjunctive minocycline in clozapine-treated schizophrenia patients with persistent symptoms","volume":"35","author":"Kelly","year":"2015","journal-title":"J. Clin. Psychopharmacol."},{"issue":"5","key":"10.1016\/j.schres.2023.08.002_bb0165","doi-asserted-by":"crossref","first-page":"1734","DOI":"10.1172\/JCI86318","article-title":"Evaluation of direct-to-consumer low-volume lab tests in healthy adults","volume":"126","author":"Kidd","year":"2016","journal-title":"J. Clin. Invest."},{"key":"10.1016\/j.schres.2023.08.002_bb0170","first-page":"117","article-title":"Treatment-resistant schizophrenia: current insights on the pharmacogenomics of antipsychotics","volume":"9","author":"Lally","year":"2016","journal-title":"Pharmgenomics Pers Med"},{"issue":"3","key":"10.1016\/j.schres.2023.08.002_bb0175","doi-asserted-by":"crossref","first-page":"328","DOI":"10.1038\/s41380-018-0335-7","article-title":"A genome-wide association study in individuals of African ancestry reveals the importance of the Duffy-null genotype in the assessment of clozapine-related neutropenia","volume":"24","author":"Legge","year":"2019","journal-title":"Mol. Psychiatry"},{"issue":"3","key":"10.1016\/j.schres.2023.08.002_bb0180","doi-asserted-by":"crossref","first-page":"239","DOI":"10.1097\/JCP.0000000000001678","article-title":"Escaping the long shadow cast by agranulocytosis: reflections on clozapine pharmacovigilance focused on the United Kingdom","volume":"43","author":"de Leon","year":"2023","journal-title":"J. Clin. Psychopharmacol."},{"issue":"3","key":"10.1016\/j.schres.2023.08.002_bb0185","doi-asserted-by":"crossref","first-page":"177","DOI":"10.1080\/17512433.2023.2183192","article-title":"Improving clozapine utilization will require continued advocacy, drug sponsor interest, and FDA support to address REMS issues","volume":"16","author":"Leung","year":"2023","journal-title":"Expert. Rev. Clin. Pharmacol."},{"issue":"Suppl. 3","key":"10.1016\/j.schres.2023.08.002_bb0190","first-page":"38","article-title":"Maximizing clozapine therapy: managing side effects","volume":"59","author":"Lieberman","year":"1998","journal-title":"J Clin Psychiatry"},{"key":"10.1016\/j.schres.2023.08.002_bb0195","doi-asserted-by":"crossref","first-page":"503","DOI":"10.1192\/bjp.158.4.503","article-title":"The effects of clozapine on tardive dyskinesia","volume":"158","author":"Lieberman","year":"1991","journal-title":"Br. J. Psychiatry"},{"issue":"1","key":"10.1016\/j.schres.2023.08.002_bb0200","doi-asserted-by":"crossref","first-page":"125","DOI":"10.1016\/S0006-3223(98)00377-1","article-title":"Smoking and therapeutic response to clozapine in patients with schizophrenia","volume":"46","author":"McEvoy","year":"1999","journal-title":"Biol. Psychiatry"},{"issue":"3","key":"10.1016\/j.schres.2023.08.002_bb0205","doi-asserted-by":"crossref","first-page":"134","DOI":"10.3371\/CSRP.6.3.5","article-title":"Clozapine: balancing safety with superior antipsychotic efficacy","volume":"6","author":"Meltzer","year":"2012","journal-title":"Clin Schizophr Relat Psychoses"},{"issue":"7","key":"10.1016\/j.schres.2023.08.002_bb0210","doi-asserted-by":"crossref","first-page":"1159","DOI":"10.1016\/j.pnpbp.2003.09.010","article-title":"Serotonin receptors: their key role in drugs to treat schizophrenia","volume":"27","author":"Meltzer","year":"2003","journal-title":"Prog. Neuro-Psychopharmacol. Biol. Psychiatry"},{"issue":"1","key":"10.1016\/j.schres.2023.08.002_bb0215","first-page":"13","article-title":"When non-whiteness becomes a condition","volume":"137","author":"Merz","year":"2021","journal-title":"Blood, The Journal of the American Society of Hematology"},{"key":"10.1016\/j.schres.2023.08.002_bb0220","series-title":"The Clozapine Handbook","author":"Meyer","year":"2020"},{"issue":"4","key":"10.1016\/j.schres.2023.08.002_bb0225","doi-asserted-by":"crossref","first-page":"167","DOI":"10.3109\/10401239509149622","article-title":"Risk factors for clozapine discontinuation among 805 patients in the VA hospital system","volume":"7","author":"Moeller","year":"1995","journal-title":"Ann. Clin. Psychiatry"},{"issue":"6","key":"10.1016\/j.schres.2023.08.002_bb0230","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0234121","article-title":"A modelling approach to estimate the prevalence of treatment-resistant schizophrenia in the United States","volume":"15","author":"Morup","year":"2020","journal-title":"PLoS One"},{"issue":"2","key":"10.1016\/j.schres.2023.08.002_bb0235","doi-asserted-by":"crossref","first-page":"185","DOI":"10.1513\/pats.200701-009GC","article-title":"Population issues in clinical trials","volume":"4","author":"Mosenifar","year":"2007","journal-title":"Proc. Am. Thorac. Soc."},{"issue":"5","key":"10.1016\/j.schres.2023.08.002_bb0240","doi-asserted-by":"crossref","first-page":"403","DOI":"10.1177\/0004867419833166","article-title":"A meta-analysis of controlled studies comparing the association between clozapine and other antipsychotic medications and the development of neutropenia","volume":"53","author":"Myles","year":"2019","journal-title":"Aust N Z J Psychiatry"},{"issue":"1","key":"10.1016\/j.schres.2023.08.002_bb0245","doi-asserted-by":"crossref","first-page":"81","DOI":"10.1016\/j.ajhg.2007.09.003","article-title":"Admixture mapping of white cell count: genetic locus responsible for lower white blood cell count in the health ABC and Jackson heart studies","volume":"82","author":"Nalls","year":"2008","journal-title":"Am. J. Hum. Genet."},{"issue":"7","key":"10.1016\/j.schres.2023.08.002_bb0250","doi-asserted-by":"crossref","first-page":"965","DOI":"10.1177\/0269881108100320","article-title":"Psychiatrists\u2019 attitude towards and knowledge of clozapine treatment","volume":"24","author":"Nielsen","year":"2010","journal-title":"J. Psychopharmacol."},{"key":"10.1016\/j.schres.2023.08.002_bb0255","unstructured":"Nutrition, A.S.f. (2021). \"Most Americans are not getting enough fiber in our diets.\" Retrieved January 30, 2023, from https:\/\/nutrition.org\/most-americans-are-not-getting-enough-fiber-in-our-diets\/."},{"issue":"2","key":"10.1016\/j.schres.2023.08.002_bb0260","doi-asserted-by":"crossref","first-page":"138","DOI":"10.3371\/CSRP.4.2.5","article-title":"Lithium to allow clozapine prescribing in benign ethnic neutropenia","volume":"4","author":"Nykiel","year":"2010","journal-title":"Clin Schizophr Relat Psychoses"},{"issue":"13","key":"10.1016\/j.schres.2023.08.002_bb0265","doi-asserted-by":"crossref","first-page":"845","DOI":"10.2165\/00023210-200418130-00002","article-title":"Starting clozapine in the community: a UK perspective","volume":"18","author":"O'Brien","year":"2004","journal-title":"CNS Drugs"},{"issue":"3","key":"10.1016\/j.schres.2023.08.002_bb0270","doi-asserted-by":"crossref","DOI":"10.1097\/MPH.0000000000000528","article-title":"Identification and clinical characterization of children with benign ethnic neutropenia","volume":"38","author":"Ortiz","year":"2016","journal-title":"J. Pediatr. Hematol. Oncol."},{"issue":"1","key":"10.1016\/j.schres.2023.08.002_bb0275","doi-asserted-by":"crossref","first-page":"39","DOI":"10.1111\/j.1600-0447.2011.01776.x","article-title":"Reason for clozapine cessation","volume":"125","author":"Pai","year":"2012","journal-title":"Acta Psychiatr. Scand."},{"issue":"10","key":"10.1016\/j.schres.2023.08.002_bb0280","first-page":"625","article-title":"The genetics of benign neutropenia","volume":"13","author":"Paz","year":"2011","journal-title":"Isr. Med. Assoc. J."},{"issue":"5","key":"10.1016\/j.schres.2023.08.002_bb0285","doi-asserted-by":"crossref","first-page":"291","DOI":"10.1097\/00004850-200109000-00007","article-title":"A comparison of smoking behaviours between patients treated with clozapine and depot neuroleptics","volume":"16","author":"Procyshyn","year":"2001","journal-title":"Int. Clin. Psychopharmacol."},{"issue":"959","key":"10.1016\/j.schres.2023.08.002_bb0290","doi-asserted-by":"crossref","first-page":"545","DOI":"10.1136\/pgmj.2004.031161","article-title":"Clozapine, agranulocytosis, and benign ethnic neutropenia","volume":"81","author":"Rajagopal","year":"2005","journal-title":"Postgrad. Med. J."},{"issue":"1","key":"10.1016\/j.schres.2023.08.002_bb0295","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pgen.1000360","article-title":"Reduced neutrophil count in people of African descent is due to a regulatory variant in the Duffy antigen receptor for chemokines gene","volume":"5","author":"Reich","year":"2009","journal-title":"PLoS Genet."},{"issue":"11","key":"10.1016\/j.schres.2023.08.002_bb0300","doi-asserted-by":"crossref","first-page":"e1454","DOI":"10.4088\/JCP.15m10315","article-title":"Evaluation of the safety of clozapine use in patients with benign neutropenia","volume":"77","author":"Richardson","year":"2016","journal-title":"J Clin Psychiatry"},{"key":"10.1016\/j.schres.2023.08.002_bb0305","doi-asserted-by":"crossref","first-page":"11","DOI":"10.1111\/j.1600-0447.1970.tb02066.x","article-title":"A rating scale for extrapyramidal side effects","volume":"212","author":"Simpson","year":"1970","journal-title":"Acta Psychiatr. Scand. Suppl."},{"issue":"5","key":"10.1016\/j.schres.2023.08.002_bb0310","doi-asserted-by":"crossref","first-page":"385","DOI":"10.1192\/bjp.bp.115.177261","article-title":"Clozapine v. first- and second-generation antipsychotics in treatment-refractory schizophrenia: systematic review and meta-analysis","volume":"209","author":"Siskind","year":"2016","journal-title":"Br. J. Psychiatry"},{"issue":"3","key":"10.1016\/j.schres.2023.08.002_bb0315","doi-asserted-by":"crossref","first-page":"222","DOI":"10.1503\/jpn.200061","article-title":"Consensus statement on the use of clozapine during the COVID-19 pandemic","volume":"45","author":"Siskind","year":"2020","journal-title":"J. Psychiatry Neurosci."},{"issue":"4","key":"10.1016\/j.schres.2023.08.002_bb0320","doi-asserted-by":"crossref","first-page":"271","DOI":"10.4103\/0019-5545.37668","article-title":"Clozapine: current perspective","volume":"49","author":"Solanki","year":"2007","journal-title":"Indian J. Psychiatry"},{"issue":"1","key":"10.1016\/j.schres.2023.08.002_bb0325","doi-asserted-by":"crossref","first-page":"30","DOI":"10.4088\/JCP.v64n0107","article-title":"Prior antipsychotic prescribing in patients currently receiving clozapine: a case note review","volume":"64","author":"Taylor","year":"2003","journal-title":"J Clin Psychiatry"},{"key":"10.1016\/j.schres.2023.08.002_bb0330","series-title":"Clozapine for Treating Schizophrenia: A Comparison of the States","author":"Torrey","year":"2015"},{"issue":"3","key":"10.1016\/j.schres.2023.08.002_bb0335","doi-asserted-by":"crossref","first-page":"483","DOI":"10.1093\/schbul\/sbm111","article-title":"The use of individually tailored environmental supports to improve medication adherence and outcomes in schizophrenia","volume":"34","author":"Velligan","year":"2008","journal-title":"Schizophr. Bull."},{"key":"10.1016\/j.schres.2023.08.002_bb0340","article-title":"Risks and benefits of clozapine and lithium co-prescribing: A systematic review and expert recommendations","author":"Verdoux","year":"2023","journal-title":"Schizophr. Res."},{"issue":"5","key":"10.1016\/j.schres.2023.08.002_bb0345","doi-asserted-by":"crossref","first-page":"921","DOI":"10.1093\/schbul\/sbr041","article-title":"Pathways to aggression in schizophrenia affect results of treatment","volume":"37","author":"Volavka","year":"2011","journal-title":"Schizophr. Bull."},{"key":"10.1016\/j.schres.2023.08.002_bb0350","doi-asserted-by":"crossref","DOI":"10.1016\/j.ajp.2021.102658","article-title":"Clozapine prescribing and safety during COVID-19","volume":"60","author":"Wadoo","year":"2021","journal-title":"Asian J. Psychiatr."},{"issue":"1","key":"10.1016\/j.schres.2023.08.002_bb0355","doi-asserted-by":"crossref","first-page":"31","DOI":"10.1093\/oxfordjournals.schbul.a006924","article-title":"Antipsychotic prescribing practices in the Veterans Healthcare Administration--New York metropolitan region","volume":"28","author":"Weissman","year":"2002","journal-title":"Schizophr. Bull."},{"issue":"2","key":"10.1016\/j.schres.2023.08.002_bb0360","doi-asserted-by":"crossref","first-page":"282","DOI":"10.1002\/ajmg.b.30811","article-title":"Dopamine transporter polymorphism modulates oculomotor function and DAT1 mRNA expression in schizophrenia","volume":"150B","author":"Wonodi","year":"2009","journal-title":"Am. J. Med. Genet. B Neuropsychiatr. Genet."},{"issue":"7","key":"10.1016\/j.schres.2023.08.002_bb0365","doi-asserted-by":"crossref","first-page":"665","DOI":"10.1001\/archgenpsychiatry.2011.71","article-title":"Downregulated kynurenine 3-monooxygenase gene expression and enzyme activity in schizophrenia and genetic association with schizophrenia endophenotypes","volume":"68","author":"Wonodi","year":"2011","journal-title":"Arch. Gen. Psychiatry"},{"issue":"suppl_1","key":"10.1016\/j.schres.2023.08.002_bb0375","doi-asserted-by":"crossref","first-page":"S67","DOI":"10.1093\/schbul\/sbx021.178","article-title":"Benign ethnic neutropenia in a sample of Nigerian healthy controls and clozapine-treated schizophrenia patients with DARC null variant","volume":"43","author":"Wonodi","year":"2017","journal-title":"Schizophr. Bull."},{"issue":"11","key":"10.1016\/j.schres.2023.08.002_bb0380","doi-asserted-by":"crossref","first-page":"968","DOI":"10.3109\/00048674.2011.607426","article-title":"Clozapine use in schizophrenia: findings of the research on Asia psychotropic prescription (REAP) studies from 2001 to 2009","volume":"45","author":"Xiang","year":"2011","journal-title":"Aust N Z J Psychiatry"},{"issue":"8","key":"10.1016\/j.schres.2023.08.002_bb0385","doi-asserted-by":"crossref","first-page":"578","DOI":"10.5414\/CP203864","article-title":"Evaluation of bioequivalence between generic and brand-name clozapine in Chinese schizophrenic patients: A randomized, two-period, crossover study","volume":"59","author":"Yang","year":"2021","journal-title":"Int. J. Clin. Pharmacol. Ther."},{"issue":"6","key":"10.1016\/j.schres.2023.08.002_bb0390","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0021040","article-title":"Population-based biochemistry, immunologic and hematological reference values for adolescents and young adults in a rural population in Western Kenya","volume":"6","author":"Zeh","year":"2011","journal-title":"PLoS One"}],"container-title":["Schizophrenia Research"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0920996423002608?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0920996423002608?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2024,10,17]],"date-time":"2024-10-17T17:04:26Z","timestamp":1729184666000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0920996423002608"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,6]]},"references-count":77,"alternative-id":["S0920996423002608"],"URL":"https:\/\/doi.org\/10.1016\/j.schres.2023.08.002","relation":{},"ISSN":["0920-9964"],"issn-type":[{"value":"0920-9964","type":"print"}],"subject":[],"published":{"date-parts":[[2024,6]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Clozapine and neutrophil response in patients of African descent: A six-month, multinational, prospective, open-label clinical trial","name":"articletitle","label":"Article Title"},{"value":"Schizophrenia Research","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.schres.2023.08.002","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2023 Elsevier B.V. All rights reserved.","name":"copyright","label":"Copyright"}]}}